STXS

AI Memo

Stereotaxis

As of 2026-09-30/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

First U.S. GenesisX installation • 2026-12-20

Base target: $1 / p=45% prob

Biggest risk

Q2 system revenue fell to $1.5 million from $3.0 million a year earlier, the net loss widened to $4.5 million, and manufacturing constraints weighed on procedures. The cash balance is modest relative to quarterly cash burn, so delays could raise financing risk [#SEC-8K-2026-08-11].

Invalidation

Break below $1 or thesis failure.

What would change my mind?

New catheter revenue, initial Synchrony sales and the first U.S. GenesisX purchase provide tangible signs of adoption. Delivering the stated Q3–Q4 recurring-revenue ramp could validate management's commercialization thesis [#SEC-8K-2026-08-11].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-30

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

MAGiC manufacturing and recurring-revenue ramp
Cash-flow profitability objective
New catheter revenue, initial Synchrony sales and the first U.S.

BearKey bullets

MAGiC supply constraints may delay the recurring-revenue ramp [#SEC-8K-2026-08-11].
Negative free cash flow and Robocath integration costs could pressure liquidity if the first-half 2027 profitability objective slips [#SEC-8K-2026-08-11].
System purchases and installations may not translate promptly into sustained utilization or recurring sales [#SEC-8K-2026-08-11].

WatchKey bullets

First U.S.

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +43% / -54%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $1 (p=30%)

Commentary

Primary-source operating news is encouraging but early-stage. The packet provides no reliable post-release price reaction, analyst revisions, social-coverage measure, options skew, short-interest figure or employee score; the zero sentiment fields denote unavailable data, not neutral measurements. Low coverage and a loose peer set warrant monitoring rather than a high-conviction call.

As of 2026-09-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

MAGiC manufacturing and recurring-revenue ramp
Cash-flow profitability objective

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-09-30 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-20
First U.S. GenesisX installation
The company reported its first U.S. hospital purchase of a GenesisX robotic system and said installation was planned for fall 2026. Completion and subsequent utilization would provide a more concrete adoption signal; the installation date and procedure volumes remain unconfirmed [#SEC-8K-2026-08-11].
Prob 70.00% • Move 12.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

MAGiC manufacturing and recurring-revenue ramp
2026-12-31
Q2 robotic-catheter revenue exceeded $1 million, while management attributed procedural pressure partly to limited catheter supply. It forecast recurring revenue of approximately $7 million in Q3 and $8 million in Q4, contingent on increasing MAGiC manufacturing. Achievement, rather than the forecast alone, would strengthen the commercialization case [#8-K-2026-08-11] [#SEC-8K-2026-08-11].
Prob 60% • Move 18% • Priced-in 45%

Long-term Catalysts

Months to a year

Cash-flow profitability objective
2027-06-30
Management anticipates cash-flow profitability in the first half of 2027 while integrating Robocath. Q2 free cash flow was negative $3.7 million against $10.5 million of June 30 cash, making revenue conversion and spending discipline critical [#SEC-8K-2026-08-11].
Prob 40% • Move 30% • Priced-in 30%

Risks

MAGiC supply constraints may delay the recurring-revenue ramp [#SEC-8K-2026-08-11].
Negative free cash flow and Robocath integration costs could pressure liquidity if the first-half 2027 profitability objective slips [#SEC-8K-2026-08-11].
System purchases and installations may not translate promptly into sustained utilization or recurring sales [#SEC-8K-2026-08-11].

Peers

Symbol	Summary
ABT	Has cardiac-device exposure, but its much larger, diversified business limits direct comparison with Stereotaxis's commercialization and funding risks.
BSX	Relevant cardiovascular and electrophysiology-device reference, but its scale and diversification make it a poor direct valuation comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-30

Loading AI feed…

Symbol

Summary

ABT

Has cardiac-device exposure, but its much larger, diversified business limits direct comparison with Stereotaxis's commercialization and funding risks.

BSX

Relevant cardiovascular and electrophysiology-device reference, but its scale and diversification make it a poor direct valuation comparable.